FDA
-
-
-
-
-
-
-
Sienna Biopharmaceuticals Announces SNA-120 (0.05%) Biopsy Data Demonstrate Positive Impact on Key Inflammatory Cytokines, including IL-23 and IL-17, in Psoriasis
-
-
-
-
-
-
324,765 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

